CTI BioPharma Corp. (NASDAQ: CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE